Perry Nisen
From Wikipedia, the free encyclopedia
BornJuly 27, 1955
AlmamaterStanford, Albert Einstein College of Medicine
KnownforCancer drug discovery and development, clinical trial data sharing, deletions by transposons, X-recessive disorders in females, molecular genetics of human cancers
FieldsMolecular Biology, Clinical Translation, Drug Discovery and Development, Clinical Data Sharing, Executive Management, Governance
Perry Nisen | |
|---|---|
 | |
| Born | July 27, 1955 |
| Alma mater | Stanford, Albert Einstein College of Medicine |
| Known for | Cancer drug discovery and development, clinical trial data sharing, deletions by transposons, X-recessive disorders in females, molecular genetics of human cancers |
| Scientific career | |
| Fields | Molecular Biology, Clinical Translation, Drug Discovery and Development, Clinical Data Sharing, Executive Management, Governance |
| Institutions | Sanford Burnham Prebys Medical Discovery Institute GlaxoSmithKline, Abbott Laboratories |
| Thesis | Flexible Genomes: Observations on the Rearrangement of DNA Sequences |
| Doctoral advisor | Stanley Norman Cohen (pre-doctoral), Lucy Shapiro(doctoral) |
Perry Nisen is an American physician and the former chief executive officer (CEO) of the Sanford Burnham Prebys Medical Discovery Institute (SBP), and held the Donald Bren Chief Executive Chair.[1][2]
Nisen received his B.S. degree from Stanford University, M.D. and Ph.D. from the Albert Einstein College of Medicine, and has been a resident at Columbia University College of Physicians and Surgeons.[3]
